← Leaderboards
Brian F Gage
Barnes-Jewish Hospital
$6,139,966
Attributed
$6,139,966
Total exposure
10
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $839.8K · FY2005–25$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$8,837,792 · 10
AHRQ$0 · 1
By mechanism
R01$8,793,251 · 8
M01$44,541 · 3
Top collaborators
No co-investigators on record.
Most similar at Barnes-Jewish Hospital
Same institution · by research overlap
- Gregory M Lanza$17,053,599
Others in their field
Top investigators on “Warfarin”
- Marc Ivor Chimowitz · University Of Florida$28,719,234
- Dan M Roden · Vanderbilt University Medical Center$28,601,711
- Shunichi Homma · Columbia University Health Sciences$24,755,631
- Thomas L Ortel · Duke University$21,868,767
- John L Thompson · Columbia University Health Sciences$21,297,693
- Patrick M Pullicino · Univ Of Med/Dent Of Nj-Nj Medical School$18,704,777
Research focus
WarfarinHemorrhagePharmacogeneticsGenetic PolymorphismResearch PersonnelDoseVenousAlgorithmsCoagulation ProcessPreventAnticoagulant TherapyParticipantInternational Normalized RatioPharmaceutical PreparationsGrantSafetyBlood CoagulationAmericanGenesGenotypeAnticoagulantsEffectivenessGeneticAnticoagulation
Grant awards (23)
Pharmacogenetic Refinement of the Warfarin Dose Using Machine Learning$385,142
R01 · FY2025 · HL · contact PI
Pharmacogenetic Refinement of the Warfarin Dose Using Machine Learning$399,423
R01 · FY2024 · HL · contact PI
GENETICS-InFORMATICS TRIAL (GIFT) OF WARFARIN TO PREVENT DVT$839,836
R01 · FY2015 · HL · contact PI
GENETICS-InFORMATICS TRIAL (GIFT) OF WARFARIN TO PREVENT DVT$552,467
R01 · FY2014 · HL · contact PI
GENETICS-InFORMATICS TRIAL (GIFT) OF WARFARIN TO PREVENT DVT$674,980
R01 · FY2013 · HL · contact PI
GENETICS-InFORMATICS TRIAL (GIFT) OF WARFARIN TO PREVENT DVT$736,139
R01 · FY2012 · HL · contact PI
GENETICS-InFORMATICS TRIAL (GIFT) OF WARFARIN TO PREVENT DVT$744,814
R01 · FY2011 · HL · contact PI
GENETICS-InFORMATICS TRIAL (GIFT) OF WARFARIN TO PREVENT DVT$739,751
R01 · FY2010 · HL · contact PI
GENETICS-InFORMATICS TRIAL (GIFT) OF WARFARIN TO PREVENT DVT$748,623
R01 · FY2009 · HL · contact PI
VITAMIN K, VKORC1 POLYMORPHISMS, AND OSTEOPOROTIC FRACTURES$6,371
M01 · FY2007 · RR · contact PI
PHARMACOGENETICS, BIOMARKERS, AND ANTITHROMBOTIC THERAPY$270
M01 · FY2007 · RR · contact PI
Pharmacogenetics, Biomarkers, and Antithrombotic Therapy$685,622
R01 · FY2006 · HL · contact PI
PHARMACOGENETICS, BIOMARKERS, AND ANTITHROMBOTIC THERAPY$37,900
M01 · FY2006 · RR · contact PI
Pharmacogenetics, Biomarkers, and Antithrombotic Therapy$723,333
R01 · FY2005 · HL
Pharmacogenetics, Biomarkers, and Antithrombotic Therapy$725,845
R01 · FY2004 · HL
Clinic Participants$0
R01 · FY2004 · HL
Thinrs Participants$0
R01 · FY2004 · HL
Prevent Participants$0
R01 · FY2004 · HL
Pharmacogenetics, Biomarkers, and Antithrombotic Therapy$563,026
R01 · FY2003 · HL
Pharmacogenetics and Antithrombotic Therapy$130,690
R01 · FY2003 · HL
Pharmacogenetics and Antithrombotic Therapy$143,560
R01 · FY2002 · HL
OPTIMAL ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION$0
R01 · FY2001 · HS
OPTIMAL ANTITHROMBOTIC THERAPY IN ATRIAL FIBRILLATION$0
R01 · FY2000 · HS